It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.

 

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Code Name Price % Six Months % Month % Week Market Cap
NEU Neuren Pharmaceut. 3.2 146 81 78 $ 409,388,447.00
ALT Analytica Limited 0.002 -33 0 33 $ 9,227,602.26
CMP Compumedics Limited 0.395 7 4 16 $ 63,778,661.28
BXN Bioxyne Ltd 0.025 32 -14 14 $ 16,003,634.95
OCC Orthocell Limited 0.575 0 14 12 $ 100,086,033.18
AMT Allegra Orthopaedics 0.17 -32 -19 10 $ 17,758,064.51
RHT Resonance Health 0.115 -39 5 10 $ 52,997,977.82
RCE Recce Pharmaceutical 0.93 -15 -2 9 $ 162,491,636.95
ADR Adherium Ltd 0.012 -33 0 9 $ 26,444,034.49
TLX Telix Pharmaceutical 7.16 55 -2 8 $ 1,967,003,065.20
MVP Medical Developments 5.2 9 3 8 $ 362,102,689.56
EYE Nova EYE Medical Ltd 0.34 11 -16 6 $ 43,666,137.30
SOM SomnoMed Limited 2.32 -6 -6 6 $ 192,001,610.80
RNO Rhinomed Ltd 0.29 93 0 5 $ 69,797,511.30
PXS Pharmaxis Ltd 0.105 31 -13 5 $ 53,572,722.37
ACR Acrux Limited 0.105 -25 -13 5 $ 28,368,033.80
TSN The Sust Nutri Grp 0.245 -44 7 4 $ 24,276,596.25
RGS Regeneus Ltd 0.074 -14 6 4 $ 22,063,457.81
ONE Oneview Healthcare 0.25 -38 -31 4 $ 118,143,984.60
TRP Tissue Repair 0.53 4 $ 22,365,155.80
VLS Vita Life Sciences.. 1.75 48 -6 3 $ 92,142,071.00
HXL Hexima 0.35 112 -3 3 $ 52,796,578.68
ATX Amplia Therapeutics 0.18 -24 -7 3 $ 27,918,187.38
CGS Cogstate Ltd 2.3 149 5 2 $ 405,613,910.40
CAN Cann Group Ltd 0.29 -30 2 2 $ 99,423,533.36
PGC Paragon Care Limited 0.305 5 0 2 $ 107,177,213.20
CAJ Capitol Health 0.36 1 9 1 $ 362,634,129.20
PBP Probiotec Limited 2.15 8 1 0 $ 175,658,556.96
BDX Bcaldiagnostics 0.13 -13 0 $ 17,098,453.06
SCU Stemcell United Ltd 0.014 -18 0 0 $ 14,606,489.21
ONT 1300 Smiles Limited 7.13001 18 1 0 $ 168,827,114.70
MMJ MMJ Group Hlds Ltd 0.066 -22 -6 0 $ 15,176,963.01
MEB Medibio Limited 0.007 -7 -13 0 $ 12,565,430.49
IRX Inhalerx Limited 0.09 -5 -10 0 $ 15,162,026.13
JTL Jayex Technology Ltd 0.021 -32 -9 0 $ 5,233,799.32
IVX Invion Ltd 0.018 13 -22 0 $ 115,384,745.32
IPD Impedimed Limited 0.17 42 -6 0 $ 301,888,125.34
IMM Immutep Ltd 0.475 -27 -29 0 $ 397,167,102.47
ICS ICSGlobal Limited 0.575313 1 0 0 $ 6,054,604.94
FFC Farmaforce Ltd 0.046 -34 -10 0 $ 6,011,325.08
CDY Cellmid Limited 0.056 -15 -10 0 $ 12,552,394.37
CDX Cardiex Limited 0.052 -36 -17 0 $ 56,237,825.60
BOT Botanix Pharma Ltd 0.056 -18 -13 0 $ 52,549,672.00
AVE Avecho Biotech Ltd 0.015 -17 -17 0 $ 23,869,514.84
AHKDB Ark Mines Limited 0.034 0 0 0 $ 88,946.01
AHC Austco Healthcare 0.13 30 -10 0 $ 36,944,563.63
AGH Althea Group 0.235 -31 -16 0 $ 74,983,445.52
AC8 Auscann Grp Hlgs Ltd 0.083 -28 -14 0 $ 36,345,136.58
MVF Monash IVF Group Ltd 0.92 5 -5 -1 $ 354,567,704.40
PIQ Proteomics Int Lab 1.18 11 13 -1 $ 122,560,815.00
GSS Genetic Signatures 1.3 7 -2 -1 $ 181,732,232.42
BWX BWX Limited 4.3 -16 -10 -1 $ 672,512,354.14
RAC Race Oncology Ltd 3.27 -13 -5 -1 $ 468,075,167.66
TRU Truscreen 0.069 -3 -14 -1 $ 24,674,905.20
PNV Polynovo Limited 1.435 -45 -18 -2 $ 975,547,364.90
HCT Holista CollTech Ltd 0.05 -18 -12 -2 $ 13,767,454.35
EZZ EZZ Life Science 0.46 6 -6 -2 $ 5,400,000.00
PAB Patrys Limited 0.037 24 0 -3 $ 74,042,010.32
CTE Cryosite Limited 0.35 -3 -1 -3 $ 17,083,347.05
OPT Opthea Limited 1.16 -21 -7 -3 $ 403,867,672.00
PAA Pharmaust Limited 0.095 -3 -14 -3 $ 29,472,851.62
MX1 Micro-X Limited 0.29 -12 -5 -3 $ 124,234,491.15
PYC PYC Therapeutics 0.14 -24 -3 -3 $ 445,329,654.42
ILA Island Pharma 0.27 -25 -10 -4 $ 11,675,654.82
BNO Bionomics Limited 0.125 -34 9 -4 $ 122,111,609.28
M7T Mach7 Tech Limited 0.85 -21 -1 -4 $ 199,320,282.00
PSQ Pacific Smiles Grp 2.78 3 -6 -4 $ 435,658,690.74
MEM Memphasys Ltd 0.091 44 15 -4 $ 72,880,407.00
RAD Radiopharm 0.34 -4 $ 40,250,109.48
LBT LBT Innovations 0.09 10 -10 -4 $ 23,996,558.61
TD1 Tali Digital Limited 0.021 -38 -30 -5 $ 18,638,115.78
NYR Nyrada Inc. 0.21 -34 -18 -5 $ 27,038,626.34
NC6 Nanollose Limited 0.1 8 -17 -5 $ 15,633,068.64
MXC Mgc Pharmaceuticals 0.039 -17 -19 -5 $ 99,335,579.33
NTI Neurotech Intl 0.058 7 -6 -5 $ 37,649,616.80
VTI Vision Tech Inc 0.85 -35 -14 -5 $ 20,681,062.50
RSH Respiri Limited 0.056 -36 -2 -5 $ 43,370,447.40
ADO Anteotech Ltd 0.185 -31 -10 -5 $ 355,327,990.56
MDR Medadvisor Limited 0.365 22 -4 -5 $ 137,793,290.73
OIL Optiscan Imaging 0.175 -44 -19 -5 $ 111,273,408.36
CHM Chimeric Therapeutic 0.255 -15 -19 -6 $ 57,298,101.64
NXS Next Science Limited 1.17 -37 -5 -6 $ 238,558,560.35
ALC Alcidion Group Ltd 0.32 -26 -14 -6 $ 335,382,096.64
LDX Lumos Diagnostics 0.875 5 -6 $ 123,350,131.80
EXL Elixinol Wellness 0.078 -44 -14 -6 $ 25,588,805.26
DXB Dimerix Ltd 0.23 -6 -6 -6 $ 73,800,943.18
UBI Universal Biosensors 0.83 26 11 -6 $ 143,978,996.88
PTX Prescient Ltd 0.225 36 -20 -6 $ 136,211,190.78
OVN Oventus Medical Ltd 0.09 -23 -18 -6 $ 21,030,208.55
CPH Creso Pharma Ltd 0.09 -44 -33 -6 $ 108,730,054.80
GLH Global Health Ltd 0.37 -53 -4 -6 $ 20,379,381.12
MDC Medlab Clinical Ltd 0.145 -26 -22 -6 $ 49,615,472.30
RHY Rhythm Biosciences 1.71 74 -14 -7 $ 348,825,059.27
NOX Noxopharm Limited 0.4 -39 -19 -7 $ 116,895,180.00
VHT Volpara Health Tech 1.06 -13 -11 -7 $ 263,920,735.05
CYC Cyclopharm Limited 1.68 -40 -13 -7 $ 158,737,199.10
SDI SDI Limited 1.02 12 1 -7 $ 124,214,478.85
ACW Actinogen Medical 0.12 -23 -31 -8 $ 220,631,275.75
1ST 1St Group Ltd 0.012 -44 -25 -8 $ 6,045,311.12
CU6 Clarity Pharma 0.825 -23 -8 $ 138,152,070.14
ARX Aroa Biosurgery 1.05 -7 -4 -8 $ 360,665,270.88
ATH Alterity Therap Ltd 0.023 -18 -21 -8 $ 52,951,240.72
ZLD Zelira Therapeutics 0.034 -31 -15 -8 $ 45,944,339.11
IMC Immuron Limited 0.11 -31 -12 -8 $ 23,895,857.58
GTG Genetic Technologies 0.0055 -31 -15 -8 $ 50,786,808.29
CYP Cynata Therapeutics 0.48 -17 -19 -9 $ 71,638,297.00
OSX Osteopore Limited 0.21 -53 -16 -9 $ 25,799,012.36
EPN Epsilon Healthcare 0.105 -34 -13 -9 $ 20,234,229.65
ZNO Zoono Group Ltd 0.36 -51 -17 -9 $ 61,165,701.59
S66 Star Combo 0.255 9 -27 -9 $ 34,351,679.60
PAR Paradigm Bio. 1.9 -11 -21 -10 $ 441,535,842.30
DVL Dorsavi Ltd 0.019 -37 -17 -10 $ 6,677,218.87
BPH BPH Energy Ltd 0.037 -57 -31 -10 $ 24,602,017.39
BIT Biotron Limited 0.083 63 69 -10 $ 52,644,953.48
NSB Neuroscientific 0.32 5 -10 -10 $ 45,910,925.76
CBL Control Bionics 0.45 -18 -4 -10 $ 24,410,489.41
BD1 Bard1 Life Sciences 1.035 -45 1 -10 $ 94,319,165.45
ALA Arovella Therapeutic 0.035 -17 -15 -10 $ 16,832,230.80
VBS Vectus Biosystems 1.2 30 -27 -10 $ 39,382,413.29
OSL Oncosil Medical 0.04 -35 -13 -11 $ 31,693,731.76
PAL Palla Pharma Ltd 0.345 -14 3 -12 $ 61,527,001.94
ICR Intelicare Holdings 0.088 -61 -18 -12 $ 4,306,183.20
ANP Antisense Therapeut. 0.18 -16 -20 -12 $ 118,405,741.50
RAP Resapp Health Ltd 0.057 12 10 -12 $ 48,974,233.39
IMU Imugene Limited 0.48 30 -19 -13 $ 2,763,075,336.96
1AD Adalta Limited 0.074 -51 -17 -13 $ 18,669,015.67
IHL Incannex Healthcare 0.495 80 -5 -13 $ 580,093,441.44
OSP Osprey Med Inc 0.655 -59 -26 -13 $ 17,447,808.56
4DX 4Dmedical Limited 1.185 -7 -14 -14 $ 252,836,473.23
IBX Imagion Biosys Ltd 0.075 -35 6 -14 $ 81,834,352.98
LCT Living Cell Tech. 0.006 -48 -22 -14 $ 6,882,439.80
SHG Singular Health 0.26 -20 11 -15 $ 17,790,707.55
PCK Painchek Ltd 0.054 -21 15 -16 $ 63,381,068.74
DOC Doctor Care Anywhere 0.45 -50 -27 -16 $ 89,397,025.39
KZA Kazia Therapeutics 1.17 -6 -25 -17 $ 157,074,367.67
IDT IDT Australia Ltd 0.52 73 12 -17 $ 123,527,987.55
AT1 Atomo Diagnostics 0.18 6 -28 -20 $ 75,607,712.35

 

The biggest winner was Neuren Pharmaceuticals (ASX:NEU) up 78%, after announcing it’s close to launching the first ever drug for Rett syndrome to the market.

The company announced that its North American partner, Acadia Pharma (Nasdaq: ACAD) reported positive top-line results from the Phase 3 Lavender study of trofinetide, which means the $400m-capped Neuren now has the potential to earn material revenues to the tune of hundreds of millions if the drug gets approved by the FDA.

A Pre-New Drug Application meeting with the FDA is planned for Q1 2022, with the all important New Drug Application (NDA) slated for mid-year.

“We’ll be the first ever treatment that’s ever approved for Rett, and that’s groundbreaking,” CEO Jon Pilcher told Stockhead.

Analytica (ASX:ALT) was up 33% on no news, followed by Compumedics (ASX:CMP) up 16% after Victorian Minister for Industry Support and Recovery Martin Pakula announced that the company will manufacture its Somfit medical-grade wearable sleep monitoring device at its global headquarters in Abbotsford after a decade of manufacturing most of its products overseas.

The project will represent the first volume manufacturing of wearable medical-grade monitoring technology in Australia – creating 33 jobs in engineering, design and ICT in the state over three years.

Compumedics is targeting an estimated export market value of $60 million over five years.

Up 14% was Bioxyne (ASX:BXN), followed by Orthocell (ASX:OCC) which rose 12% after releasing study results which show its OrthoATI treatment is “significantly” more effective than steroid injection for the treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

Allegra Orthopaedics (ASX:AMT) rose 10% on no news, with Resonance Health (ASX:RHT) also up 10% after submitting its LiverSmart AI medical device to the FDA for US regulatory clearance.

 

Who flatlined?

Flat was Immutep (ASX:IMM), which reported good safety from the first five patients in triple combination therapy EFTU study Insight-003.

The study will continue to recruit up to 20 patients with various solid tumours and additional results are expected in CY22.

Then there was Avecho Biotech (ASX:AVE), which released the results for its Australian Phase I PK study which characterises the absorption profile of cannabidiol from its CBD soft-gel product.

We now understand the absorption profile from both doses of our proprietary CBD soft-gel in humans,” CEO Dr Paul Gavin said.

“The results are exciting and show that the delivery profiles from both doses could support utility across a range of potential indications, whether they require once per day, or twice per day, dosing.”

 

Who’s the biggest loser?

The biggest loser was Atomo Diagnostics (ASX:AT1), down 20% on no news.

Followed by IDT Australia (ASX:IDT), down 17%. The company recently announced it had successfully manufactured Australia’s first mRNA COVID-19 vaccine candidate.

The company said it has met all specifications and will provide the drugs to the Monash Institute of Pharmaceutical Sciences (MIPS), as part of its mRNA COVID-19 receptor binding domain vaccine clinical trial.

Also down 17% was oncology-focused company Kazia Therapeutics (ASX:KZA) which released positive final data from its Phase II clinical study of paxalisib for glioblastoma – with results confirming the previously reported safety and efficacy profile of the treatment.